Foghorn therapeutics announces new data demonstrating brd9 degradation in patient tumor biopsies and discloses new selective cbp program

Initial phase 1 data of fhd-609 show degradation of brd9 in on-treatment metastatic tumor synovial sarcoma biopsies

FHTX Ratings Summary

FHTX Quant Ranking